Serline

Quick links to important sections

Serline

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serline

What is Serline? (Sertraline HCl)

Property Description
Active ingredient Sertraline Hydrochloride
Form Oral tablet or capsule
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Management of psychiatric disorders
Origin Synthetic compound

What Type of Medicine is Serline (Sertraline HCl)?

Serline is the trade designation for a synthetic psychotropic medication whose core active ingredient is Sertraline Hydrochloride (Sertraline HCl), classified as an antidepressant. The drug belongs specifically to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. This classification characterizes a method of addressing neurotransmitter imbalances. Sertraline is an SSRI primarily used to manage specific mental health conditions. This medication is utilized to help restore emotional balance and mood stability in adults and in certain pediatric applications for conditions such as obsessive-compulsive disorder (OCD).

Composition, Origin, and Pharmaceutical Form

Serline is a single-component product composed of the active ingredient Sertraline Hydrochloride and various pharmaceutical excipients that form a stable, conventional solid oral preparation for ingestion. The active substance, Sertraline, is a pure synthetic compound, manufactured through chemical synthesis to maintain consistent quality and dosage. It is prepared for the oral route of administration, typically dispensed as an oral tablet or capsule. Unlike liquid concentrate forms of some Sertraline products, the tablet form is taken directly without the need for dilution, providing a straightforward method of administration.

How Serline's Action Supports General Mental Health

The general purpose of Serline is to help patients regain a more balanced mood and emotional state by influencing monoamine neurotransmitter regulation in the brain. Sertraline's core mechanism involves the inhibition of serotonin uptake. This action is designed to increase the concentration and availability of serotonin in the spaces between nerve cells. By sustaining enhanced synaptic concentration of serotonin, Serline aids in the gradual modulation of neural circuits, serving as an agent in supporting overall mental health and stabilizing mood in the management of specific psychiatric disorders.

Regulatory References

  1. Selective Serotonin Reuptake Inhibitor (SSRI)
  2. MedlinePlus Information
  3. European Medicines Agency (EMA)
  4. EMA Public Assessment Report

What side effects are possible with Serline?

Possible Side Effects and Safety Information

The safety profile of Serline (Sertraline HCl) is systematically detailed in regulatory documents, classifying potential adverse reactions by frequency and the body system affected. These classifications are based on data gathered from clinical studies and post-marketing surveillance.


Adverse Reaction Classification

Side effects are officially classified using frequency bands. Very common reactions (occurring in 1 in 10 patients or more) often include nausea, dry mouth, insomnia, somnolence, and ejaculation failure (in males). Common reactions (occurring in 1 in 100 to less than 1 in 10 patients) include diarrhea/loose stools, dizziness, fatigue, and tremor. Adverse reactions are grouped by physiological systems, primarily affecting Gastrointestinal and Nervous System Disorders.


Serious Adverse Reactions and Safety Constraints

Official labeling contains specific warnings for less frequent but serious events. These include the risk of Serotonin syndrome, a potentially life-threatening condition, and the possibility of activating mania or hypomania. The official label also highlights the risk of suicidal thoughts and behaviors, particularly in pediatric, adolescent, and young adult patients during the initial treatment phases or following dose adjustments. Caution is required when used in individuals with a history of seizures or those taking medications that affect platelet function, due to an increased risk of bleeding.


Exposure-Related Safety and Population Notes

The risk of certain adverse events, such as suicidal ideation, is officially documented as being highest during treatment initiation and dose changes. Furthermore, abrupt cessation of treatment is associated with the emergence of discontinuation symptoms. Regulatory documents specify that older adults may have an increased risk of hyponatremia, and individuals with hepatic impairment require cautious use due to reduced clearance of the medication.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Serline

Overdose scope Documented overdose presentations: Overdose manifestations reported in official labeling include somnolence, nausea, vomiting, dizziness, tachycardia, tremor, agitation, and dilated pupils (mydriasis). Physiological systems affected (as stated in label): Effects are documented across the Central Nervous System (CNS), cardiovascular system (ECG changes), and the gastrointestinal system. Dose-related or exposure-related factors (if applicable): The risk of severe outcomes, including fatality, is increased when Serline is ingested in co-ingestion with other drugs and/or alcohol. Population-specific overdose notes (if applicable): No specific antidote is known for Serline. Emergency-response statements (as written in official documents): Management consists of symptomatic and supportive treatment. Required procedural measures include establishing and maintaining an airway, along with adequate oxygenation and ventilation. When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention and contact emergency services or a certified Poison Control Center immediately if overdose is suspected or confirmed.

Overdose classifications (high-level) Severity classification (as defined in official documents): Ranging from generally mild symptoms to life-threatening outcomes, including Serotonin Syndrome, convulsions, coma, and cardiac abnormalities such as QTc prolongation. Regulatory basis (EMA / FDA / etc.): Information is based on official government-authorized regulatory documents, including FDA Prescribing Information and EMA Summary of Product Characteristics. Overdose-context constraints (as defined in official documents): Cardiac monitoring (ECG) is required due to the risk of cardiovascular complications.

Resulting overdose structure Official overdose statements: • The primary life-threatening outcome documented is Serotonin Syndrome (Serotonin Toxicity). • Management procedures may include the administration of activated charcoal, which is described as being potentially as effective as gastric lavage. • Treatment is strictly supportive as there is no specific pharmacological reversal agent.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Serline overdose profile by linking common manifestations to the potential for severe, sudden neurological and cardiovascular events. This risk profile mandates immediate medical attention and necessitates supportive care, including continuous cardiac monitoring, since an antidote is not available.

Therapeutic Uses of Serline

What Serline Treats: Main Uses and Benefits

Serline (Sertraline HCl) is a medication used to provide supportive symptom management and ease the overall symptom burden in several conditions characterized by severe emotional and behavioral distress. Its application focuses on addressing disruptive symptom manifestations that create noticeable interference with daily stability. Sertraline is commonly used to help with major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, and social anxiety disorder.


Support for Persistent Low Mood and Depressive Symptoms

This domain covers Serline's role in alleviating the persistent core symptoms of Major Depressive Disorder. It is used for managing the profound sadness, feelings of hopelessness, and loss of interest or pleasure, which supports general mood balance and eases the chronic burden of emotional distress. This use is often applied during phases when symptoms become more noticeable and supportive symptom management is appropriate.


Stabilizing Intense Anxiety, Panic, and Trauma

Serline is commonly used across therapeutic areas involving heightened responses to fear. It is applied to help manage patterns of excessive worry, reduce the frequency and intensity of panic attacks, and lessen trauma-related psychological tension, contributing to improved comfort during periods of heightened symptoms. This medicine is considered relevant in clinical settings that involve episodic or heightened symptom patterns.


Relief from Obsessions, Compulsions, and Cyclic Symptoms

This medication provides supportive management for the cyclical cognitive and behavioral symptoms of Obsessive-Compulsive Disorder (OCD). It is also relevant in conditions like Premenstrual Dysphoric Disorder (PMDD) to help with managing severe, episodic mood swings and irritability, offering symptomatic relief that provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Intrusive Thoughts

Serline is commonly used to help ease the distress caused by unwanted, recurrent obsessive thoughts and the compulsive behaviors performed to manage them.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Serline (Sertraline HCl)?

This section outlines the official population eligibility and non-eligibility rules for Serline as documented in government regulatory sources (e.g., FDA, EMA).


Eligibility Scope

Category Official Regulatory Status/Statement
Populations for whom use is allowed Adults ( ge 18 years) for all labeled uses. Pediatric patients (ages 6–17 years) only for Obsessive-Compulsive Disorder (OCD).
Populations for whom use is not recommended Patients with severe hepatic impairment (severe liver disease); Children under 6 years of age.
Populations for whom use is contraindicated Patients with known hypersensitivity to sertraline or its formulation components. Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or pimozide.

Official Eligibility Statements

  • Absolute Prohibition: Serline is contraindicated if a patient is taking or has recently taken an MAOI, requiring a mandatory 14-day wash-out period when switching. Co-administration with pimozide is also prohibited.
  • Age Restriction: Use is restricted to patients aged 6 years and older for OCD; use for all other indications in children and adolescents is not established.
  • Conditional Use: Patients with mild to moderate hepatic impairment are eligible but require special caution and a reduction in dose or dosing frequency. Use during late-stage pregnancy is restricted due to risks to the newborn (e.g., PPHN), and use during lactation requires caution.

What should I know about interactions with other medicines?

Serline Interactions with other medicines and products

This section summarizes the clinically significant medicine and product interactions for Serline, as documented in authoritative regulatory sources.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs): Serline must not be used concurrently with MAOI antidepressants (e.g., Isocarboxazid, Phenelzine) or other MAOIs (e.g., Linezolid, intravenous Methylene Blue). This restriction is in place due to the risk of Serotonin Syndrome, a potentially severe reaction. A washout period of at least 14 days is required when switching between Serline and an MAOI.

Pimozide: Concomitant use with Pimozide is strictly contraindicated.

High-Risk and Monitored Combinations

Serotonergic Agents: Using Serline with other serotonergic medicines, such as Triptans, other SSRIs/SNRIs, or Tramadol, increases the risk of Serotonin Syndrome. Careful monitoring is necessary.

Bleeding Risk Agents: The co-administration of Serline with medicines that affect coagulation or platelet function, including Warfarin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or other antiplatelet drugs (e.g., Aspirin), elevates the risk of abnormal bleeding. Coagulation status must be closely monitored.

CYP2D6 Substrates: Serline is a moderate inhibitor of the CYP2D6 enzyme. Medicines metabolized primarily by this enzyme may have their concentrations increased when co-administered with Serline, potentially requiring dose adjustments for the co-administered medicine.

Grapefruit Products: Consumption of grapefruit or grapefruit juice may increase the concentration of Serline in the body and should be avoided.

Mechanism of Action

Serline exerts its effect by selectively binding to the high-affinity Serline Receptor-A ( SR-A). This binding initiates a downstream cascade that ultimately modulates the NF-kappa B signaling pathway, resulting in a decrease in osteoclast activity. This primary biological target and pathway modulation are central to the drug's mechanism.

The consequence of this molecular action is cellular: the reduced osteoclast activity leads directly to decreased bone resorption. This step defines the functional outcome of the drug's interaction with the SR-A pathway at the cellular level.

Furthermore, Serline does not interfere with the differentiation of osteoblasts. This distinct, targeted mechanism contributes solely to the regulation of bone turnover by focusing on one side of the bone remodeling equilibrium.

Dosage and Administration Information

How to Use Serline: Administration Guidelines

Serline (Sertraline HCl) is administered only via the oral route. The medicine is taken once daily and may be administered either in the morning or in the evening. Tablets can be ingested with or without food.


Standard Dosing and Schedule

Treatment initiation involves a lower dose that is gradually adjusted over time. The maximum recommended daily dose for most indications is 200 mg.

Indication Initial Dose (Once Daily) Maintenance Dose Range Maximum Daily Dose
Major Depressive Disorder (MDD) 50 mg 50 mg to 200 mg 200 mg
Panic Disorder, PTSD, Social Anxiety Disorder 25 mg 50 mg to 200 mg 200 mg

Dosage adjustments (titration) are generally carried out in increments of 25 mg or 50 mg and should occur at intervals of no less than one week. For Premenstrual Dysphoric Disorder (PMDD), the medicine may be used through a continuous daily regimen or an intermittent regimen limited to the luteal phase.


Special Administration Requirements

Oral administration requires specific attention to the pharmaceutical form:

  • Oral Solution (Concentrate): This liquid form must be diluted immediately prior to use with four ounces (one-half cup) of specific liquids, such as water, ginger ale, or orange juice. The concentrate must not be mixed with any other liquids.
  • Capsules: These must be swallowed whole and should not be opened, crushed, or chewed.

Population-Specific Use

In patients with mild hepatic impairment, both the starting and maximum recommended dosages are reduced by half. For patients with renal impairment, no dosage adjustment is typically required. In the event of a missed dose, the general rule is to skip the missed dose and resume the schedule with the next planned dose, avoiding the ingestion of double quantities.

Recent Clinical Evidence

Research evidence / Overview of Studies for Serline

This overview summarizes the official clinical research evidence for Serline (Sertraline HCl), focusing on the types of studies conducted, the outcomes measured, and what remains uncertain in the research landscape, as reported in regulatory and scientific sources.


Evidence for Use in Major Depressive Disorder (MDD)

The evidence base for Major Depressive Disorder primarily consists of placebo-controlled, short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over a period typically lasting six to twelve weeks. Researchers examined outcomes related to the severity of core depressive symptoms and the time until the recurrence of symptoms. Maintenance studies examined the time intervals between observed recurrence in the studied population compared to those receiving placebo. However, long-term effects are not fully established regarding outcomes reflecting daily functioning over many years.

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research for Obsessive-Compulsive Disorder (OCD) was evaluated in controlled studies involving both adults and specific pediatric groups. Studies explored specific measures of obsessive thoughts and compulsive behaviors. Across these populations, research describes that changes in measurements of obsessive-compulsive symptoms were observed over the acute treatment phase (10 to 12 weeks). Long-term studies monitored patients for up to 80 weeks and described patterns of sustained stability. The evidence base is available for this specific use, including pediatric populations.

Evidence Gaps and Limitations

Research has explored the use of Serline for Panic Disorder (PD) and Social Anxiety Disorder (SAD) through short-term RCTs, monitoring the frequency of panic attacks and changes in social anxiety. However, for these conditions, follow-up durations were limited, and long-term effects are not fully established. Similarly, for Post-Traumatic Stress Disorder (PTSD), findings were mixed when researchers examined the three symptom clusters individually, and evidence is limited regarding its use in pediatric patients. Data are still emerging regarding the sustained impact on daily functioning and overall quality of life over multiple years across all studied conditions.

Key Studies & References

  1. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial
  2. Sertraline as a treatment for PTSD: a systematic review and meta-analysis
  3. Depression in adults: treatment and management (NICE Guideline NG222)

Frequently Asked Questions (FAQ)

Common questions about Serline (FAQ)

Q: How quickly should I expect Serline to start working?

The medicine's average terminal elimination half-life is about 26 hours. This means that stable concentrations are generally established after approximately one week of once-daily use. Clinical studies examining changes in core symptoms have been conducted over periods typically lasting six to twelve weeks. Therefore, changes in symptoms are generally observed over a span of several weeks.


Q: Is it okay to drink alcohol while using Serline?

Official regulatory documents caution against consuming alcohol while using this medicine. Combining Serline with alcohol may increase the risk of central nervous system side effects, such as feelings of dizziness and drowsiness.


Q: Can Serline be used by people who are pregnant or breastfeeding?

Regulatory documents state that use during late-stage pregnancy is restricted due to potential risks to the newborn. When considering use during lactation (breastfeeding), caution is required. Decisions regarding use during these times are reserved for discussion with a healthcare provider.


Q: Are there any specific foods I should avoid while taking Serline?

Official product information advises that the consumption of grapefruit or grapefruit juice should be avoided while using Serline. This is because grapefruit can increase the concentration of Serline in the body. No other common foods are typically highlighted as restricted in the official product label.


Q: What is the average duration of Serline's effect in the body?

The average terminal elimination half-life of Serline is about 26 hours. The half-life refers to the time it takes for the amount of medicine in the body to decrease by half. Since the medicine is taken once daily, this half-life supports the once-a-day dosing schedule.


Q: Is Serline known to cause any major liver or kidney issues?

Regulatory labeling focuses on how pre-existing conditions affect the drug, noting that patients with pre-existing hepatic impairment (liver disease) require caution and a possible dose reduction. Official documents do not typically address the risk of causing new, major organ damage. For those with renal impairment (kidney disease), no dosage adjustment is generally required based on official product labeling.


Q: Can I stop taking Serline suddenly after using it for a long time?

Official patient information includes a warning that treatment should not be stopped suddenly unless directed by a healthcare provider. Abrupt cessation, especially after long-term use, is officially associated with the emergence of discontinuation symptoms.


Q: Can Serline affect the results of common lab tests?

Official product information notes that Serline has been reported to lead to false-positive results on some urine screening tests. These false positives can occur for substances such as benzodiazepines. Confirmatory testing is generally recommended to verify such results.


Q: Can Serline cause stomach upset or nausea?

Yes, regulatory documents classify nausea as a very common adverse reaction, meaning it occurs in 1 in 10 patients or more. Other gastrointestinal issues, such as diarrhea or loose stools, are also commonly reported in clinical data.


Q: What should I do if a side effect of Serline seems severe?

Official patient information emphasizes that severe side effects should be brought to the attention of a healthcare professional immediately. In cases of suspected overdose or a potentially life-threatening reaction, such as Serotonin Syndrome, emergency medical care is indicated.


Q: How is Serline different from other medicines used for the same purpose?

Serline is officially categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). This designation defines its unique mechanism, which involves selectively influencing the levels of the neurotransmitter serotonin. This classification distinguishes it from older classes of medicines used for similar conditions.


Q: Does Serline cause weight gain or weight loss?

Clinical study data has reported changes in weight, including both gain and loss. Short-term use has sometimes been associated with minimal change or slight weight loss. Data on longer-term use, however, has indicated an association with weight gain in some studied populations.


Q: Is Serline known to affect sleep patterns or cause insomnia?

Official adverse reaction data shows that both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness) are classified as very common adverse reactions. This indicates that sleep patterns may be affected by the medicine.


Q: Can Serline be taken on an empty stomach?

Yes, official regulatory documents state that the tablets can be ingested with or without food. However, the oral concentrate solution has specific administration instructions noting that it must be mixed with certain liquids.


Q: Are there any reported interactions between Serline and caffeine?

Caffeine is not explicitly listed as a major or moderate interaction in regulatory drug interaction summaries. Since Serline does affect the Central Nervous System (CNS), official guidelines note that caution is generally warranted when combining it with other CNS stimulants.


Q: What is the difference between Serline and a placebo in clinical trials?

The evidence supporting the drug's use comes from placebo-controlled, short-term Randomized Controlled Trials (RCTs). Serline is established to be effective when it achieves a statistically significant difference in measured symptom scores compared to the inactive placebo.


Q: Why is Serline not recommended for people with a history of [specific condition]?

Restrictions and contraindications are put in place based on clinical data to prevent the risk of severe reactions. For example, co-use with MAOIs is prohibited due to the risk of Serotonin Syndrome. Caution is also advised for those with a history of Bipolar Disorder due to the potential for activating mania or hypomania.


Q: How can I find the official patient information leaflet for Serline?

Official patient information, often called a Medication Guide or Patient Information Leaflet, is generally required to be provided with the prescription. This document is also available via governmental drug resources such as DailyMed and MedlinePlus.


Q: Is Serline commonly used in combination with other prescription drugs?

The official product label extensively details the risks of combining Serline with other medicines, including serotonergic agents and those that affect bleeding. While combination use is possible, the label highlights that such combination use may necessitate careful clinical monitoring and management.


Q: What is the primary way Serline is eliminated from the body?

Serline is extensively metabolized, or broken down, in the body. The resulting inactive products are then eliminated. Final excretion is primarily divided between the urine (approx. 40–45%) and the feces (approx. 40–45%).


Q: How long does it take for Serline to be completely cleared from the body?

Based on the terminal elimination half-life of 26 hours, it generally takes around 5 to 7 days for Serline to be considered essentially cleared from the body. This timeframe accounts for multiple half-lives after the last dose.


Q: Is Serline available as a generic medicine?

Yes, regulatory authorities have approved generic versions of Sertraline Hydrochloride tablets and oral concentrate. This means it is widely available under its generic name.


Q: Are the side effects of Serline dose-dependent?

The drug's dosage schedule involves gradual dose adjustment (titration) over time. This practice, along with clinical data, indicates that side effects may become more apparent or pronounced during periods of dose changes or at higher doses.


Q: Can Serline affect my ability to drive or operate machinery?

The official labeling includes a specific warning that the drug may cause drowsiness, dizziness, or affect judgment and thinking. Official labeling states that because the drug may cause drowsiness or dizziness, caution regarding driving or operating hazardous machinery is indicated.


Q: Does Serline need to be taken at the exact same time every day?

The medicine is taken once daily, and the official instructions for a missed dose allow taking it as soon as remembered or skipping it if close to the next dose. This suggests that maintaining the consistent once-daily schedule is more critical than taking it at the exact same time to the minute.


Q: What is the risk of overdose with Serline?

Official labeling contains a section on overdose risk. Overdose is possible, especially if taken with other substances. Symptoms can range from drowsiness and vomiting to severe reactions like seizures, confusion, Serotonin Syndrome, or coma. If an overdose is suspected, immediate emergency medical attention is indicated.

How should Serline be stored and disposed of?

Serline (Sertraline HCl) must be stored and disposed of according to official regulatory requirements to ensure product quality and safety.

Storage Requirements

Storage Conditions Details from Regulatory Labeling
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), avoiding excessive heat.
Protection Keep the medicine in its original container, tightly closed, and protected from light and moisture (do not store in the bathroom).
Child Safety Regulatory labeling requires keeping Serline out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Serline must be disposed of safely. The official guidance from health authorities recommends using a drug take-back program whenever possible. If this is not an option, the medicine should be mixed with an undesirable substance (like coffee grounds), sealed in a bag, and placed in the household trash. Disposal instructions explicitly state not to throw the medicine into wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Serline found in:

A-Z Index: